FRANKFURT, Germany–(BusINESS WIRE)–Merz Therapeutics, onye ndu na ngalaba nke neurotoxins na azụmaahịa n'okpuru Merz Group, yana Teijin Pharma Limited, bụ isi ụlọ ọrụ azụmaahịa ahụike Teijin Group, jikọtara ọnụ na-ekwupụta taa na Teijin Pharmaceuticals emeriela mgbakwunye. nkwado sitere n'aka Ministri Ahụike, Ọrụ na ọdịmma nke Japan (MHLW) iji Xeomin® (incobotulinumtoxinA) na nkeji 50, 100 ma ọ bụ 200 nke intramuscular injections maka ọgwụgwọ spasms ụkwụ ala.
Nkwụsị ụkwụ dị ala bụ ihe mgbaàmà nke ọrịa neuron moto nke elu, bụ nke a na-egosipụtakarị site na ụbara ụda akwara nke akụkụ ahụ na oke mkpali nke mgbatị ahụ dị ka ihe na-esote ọrịa strok.Ihe mgbaàmà bụ isi bụ ihe isi ike na-eje ije na-emekarị yana ihe ize ndụ dị ukwuu nke ịdaba n'ihi ogwe anaghị akwụsi ike, mgbagwoju anya ma ọ bụ ihe mgbochi na ndụ kwa ụbọchị.Usoro ọgwụgwọ maka spasm ụkwụ na-agụnye mgbatị anụ ahụ na iji ihe na-eme ka ahụ ike nke ọnụ ma ọ bụ ihe mgbochi neuromuscular, dị ka botulinum toxin ụdị A.
Stefan Brinkmann, onye isi oche nke Merz Therapeutics, kwuru, sị: "Nkwenye agbatịkwuru bụ ihe dị mkpa maka ọgwụgwọ Merz na ọ bụ nsonaazụ nke mmekọrịta chiri anya anyị na Teijin Pharmaceuticals.Anyị nwere olile anya na ndị mmekọ anyị ga-ewebata ndị dọkịta na ndị ọrịa Japan ihe ngosi spasticity nke ọma nke ọma. ”
Dr. Stefan Albrecht, Senior Vice President of Global R & D, Merz Therapeutics: "Mgbasawanye labelụ a na Japan bụ ihe atụ ọzọ pụtara ìhè nke uru Xeomin ® na-enye ọtụtụ ndị ọrịa nwere spasticity post-stroke.Ndị dọkịta nwere ike ịhọrọ ugbu a ịgwọ spasticity dị ala na nke elu, ma ọ bụ na ha nwere ike ịgbanwe dị ka ọ dị mkpa Jiri nlezianya tinye doses nke onye ọ bụla.Obi dị anyị ụtọ maka mmezu a, ọkachasị ezigbo nkwado anyị na onye ibe anyị Teijin. "
Onye isi ala Teijin Pharmaceutical Ichiro Watanabe kwuru, sị: “Teijin Pharmaceutical na-enye ọgwụ dị iche iche, gụnyere ọgwụgwọ osteoporosis na ngwaọrụ ahụike, dị ka ụda ebili mmiri na-eme ka usoro ọgwụgwọ mgbaji gbajie ngwa ngwa maka ndị ọrịa nwere ọrịa musculoskeletal.Na nzaghachi na mgbanwe igwe mmadụ na mmụba ahụike mmata , Anyị na-ebupụta ọgwụ ọhụrụ na ngwọta dị irè, gụnyere mmezu nke ọha mmadụ na-adịgide adịgide.Teijin Pharmaceuticals na-aga n'ihu na-enye aka n'ịkwalite ndụ ndụ (QOL) nke ndị ọrịa site n'inye usoro ọgwụgwọ ọhụrụ maka ọrịa na-enweghị mkpa.”
Xeomin® na-agwọkwa njedebe akwara cholinergic nke ọma site n'ime ka mkpụkọ akwara afọ ofufo na-ebelata, ma na-ebelata ahụmịka akwara site na igbochi ntọhapụ nke neurotransmitter a na-akpọ acetylcholine.Neurotoxin a sachara nke ukwuu bụ naanị ihe na-arụ ọrụ na Xeomin®.A na-eme ya site n'iwepụ protein ndị dị mgbagwoju anya na ụdị A botulinum toxin nke Clostridium botulinum mepụtara site na iji teknụzụ nchacha nke Merz Pharma GmbH & Co. KGaA mepụtara.Enweghị protein dị mgbagwoju anya na-enye Xeomin® aka ibelata mmepụta nke mgbochi mgbochi nke nwere ike ibelata nrụpụta ọrụ.Ọganihu dị mkpa na akara Plantar flexor modified ashworth scale (MAS) ka ahụrụ na nnwale ụlọọgwụ nke Atọ na Japan.
Merz Pharmaceuticals GmbH na-ekesa Xeomin® n'ihe karịrị mba 70 ma ejiri ya na-agwọ ndị ọrịa nwere spasm elu, cervical dystonia, blepharospasm ma ọ bụ oke salivation.Teijin Pharmaceuticals bịanyere aka n'akwụkwọ ikike pụrụiche na nkwekọrịta mmepe nkwonkwo maka Xeomin® na Japan na Merz na 2017, wee malite ire ahịa Xeomin® pụrụ iche na Disemba 2020 mgbe ọ nwetasịrị nkwado n'aka Ministry of Health, Labour and Welfare (MHLW) nke Japan.Dabere na nnwale ụlọ ọgwụ Merz's Phase III na Japan, nkwado ndị enwetara ọhụrụ agbanweela ụfọdụ nkwenye akwadoro.
N'ozuzu, maka ndị okenye, ekwesịrị ịgbanye Xeomin® n'ime ọtụtụ akwara siri ike.* Oke kachasị n'otu nchịkwa bụ nkeji 400, mana ekwesịrị ibelata ya nke ọma ka ọ bụrụ nke kacha nta dịka ụdị na ọnụọgụ akwara tonic lekwasịrị anya.Ọ bụrụ na mmetụta nke ọgwụ gara aga na-ebelata, a na-anabata usoro ugboro ugboro.Ogologo oge dose kwesịrị ịbụ izu iri na abụọ ma ọ bụ karịa, mana enwere ike mbelata ya ka ọ bụrụ izu iri dabere na mgbaàmà.
* Myotonic: gastrocnemius (isi etiti, isi mpụta), soleus, tibialis azụ, flexor digitorum longus, wdg.
Merz Therapeutics bụ azụmahịa nke Merz Pharmaceuticals GmbH raara onwe ya nye iji kwalite ndụ ndị ọrịa gburugburu ụwa.Site na nyocha ya na-adịghị akwụsị akwụsị, mmepe na ọdịbendị ọhụrụ, Merz Therapeutics na-agba mbọ izute mkpa ndị ọrịa na-egbobeghị ma nweta nsonaazụ ka mma.Merz Therapeutics na-achọ igbo mkpa pụrụ iche nke ndị mmadụ na-enwe nsogbu mmegharị ahụ, ọrịa akwara ozi, ọrịa imeju, na ọnọdụ ahụike ndị ọzọ na-emetụta ụdị ndụ ndị ọrịa nke ukwuu.Merz Therapeutics bụ onye isi na Frankfurt, Germany, yana ụlọ ọrụ nnọchite anya karịa mba 90, yana alaka North America na Raleigh, North Carolina.Merz Pharmaceuticals GmbH bụ akụkụ nke Merz Group, ụlọ ọrụ nwere ezinaụlọ nwere onwe ya na-agba mbọ imepe ihe ọhụrụ na-egbo mkpa ndị ọrịa na ndị ahịa ihe karịrị afọ 110.
Teijin (Tokyo Stock Exchange code: 3401) bụ otu teknụzụ zuru ụwa ọnụ nke na-enye ihe ngwọta dị elu n'ọhịa nke uru gburugburu ebe obibi;nchekwa, nchekwa, na mbelata ọdachi;yana mgbanwe igwe mmadụ yana mmụba ahụike.Teijin e hiwere na 1918 dị ka onye mbụ rayon emeputa na Japan, na ugbu a tolitere n'ime a pụrụ iche ụlọ ọrụ na-ekpuchi atọ isi azụmahịa ebe: elu-arụmọrụ ihe gụnyere aramid, carbon eriri na ihe mejupụtara, yana resin na plastic nhazi, Film. , eriri polyester na nhazi ngwaahịa;nlekọta ahụike, gụnyere ọgwụ na akụrụngwa ahụike ụlọ maka ọkpụkpụ / nkwonkwo, usoro iku ume, na ọrịa obi / ọrịa metabolic, nọọsụ na nlekọta pre-symptomatic;na IT, gụnyere ọgwụgwọ, ụlọ ọrụ na B2B ngwọta maka usoro ọha, yana ngwanrọ ngwugwu na ọrụ B2C n'ịntanetị maka ntụrụndụ dijitalụ.Dị ka e gosipụtara na nkwupụta ika "Human Chemistry, Human Solutions", Teijin na-agbasi mbọ ike maka ndị na-eme ya ma na-achọ ịghọ ụlọ ọrụ na-akwado ọha mmadụ n'ọdịnihu.Otu a nwere ihe karịrị ụlọ ọrụ 170 ma nwee ihe dị ka ndị ọrụ 20,000 na mba / mpaghara 20 gburugburu ụwa.N'afọ mmefu ego na-agwụ na Machị 31, 2021, Teijin kwupụtara ire ere nke ijeri yen 836.5 ($ 7.7 ijeri) yana mkpokọta akụ nke 1.036.4 ijeri yen ($ 9.5 ijeri).
Oge nzipu: Sep-10-2021